Compare Amylx Pharmaceuticals Inc (AMLX) vs Cisco Systems Inc (CSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Cisco Systems Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Cisco Systems Inc trades at $121.26 (market cap $483.10B). The key difference: Cisco Systems Inc is far larger — about 190.9× Amylx Pharmaceuticals Inc's market cap, and Cisco Systems Inc pays a 1.37% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CSCO | |
|---|---|---|
Market Cap | $2.53B | $483.10B |
Sector | Health | Technology |
52-Week High | $24.19 | $130.00 |
52-Week Low | $7.82 | $66.20 |
Enterprise Value | $2.28B | $497.76B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Cisco Systems (CSCO) trades at $120.43, down 0.82% on the day, amid a bullish technical outlook and strong earnings beats. The stock shows robust fundamentals with a 64.33% gross margin and consistent quarterly EPS outperformance. Recent AI cybersecurity initiatives and partner expansions fuel positive sentiment, with a consensus price target of $133.25 implying upside potential.
The outlook remains favorable given AI-driven growth catalysts and solid cash flow, though elevated valuation ratios and competitive pressures pose risks. Analyst consensus leans bullish with 52% buy ratings, supporting a constructive view for investors seeking exposure to networking and cybersecurity trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →
